Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Jul;41(8):1974-82.
doi: 10.1038/npp.2015.367. Epub 2015 Dec 28.

Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis

Margaret Haney  1 , Robert J Malcolm  2 , Shanna Babalonis  3 , Paul A Nuzzo  3 , Ziva D Cooper  1 , Gillinder Bedi  1 , Kevin M Gray  2 , Aimee McRae-Clark  2 , Michelle R Lofwall  3 , Steven Sparenborg  4 , Sharon L Walsh  3
Affiliations
Randomized Controlled Trial

Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis

Margaret Haney et al. Neuropsychopharmacology. 2016 Jul.

Abstract

Cannabidiol (CBD), a constituent of cannabis with few psychoactive effects, has been reported in some studies to attenuate certain aspects of Δ(9)-tetrahydrocannabinol (THC) intoxication. However, most studies have tested only one dose of CBD in combination with one dose of oral THC, making it difficult to assess the nature of this interaction. Further, the effect of oral CBD on smoked cannabis administration is unknown. The objective of this multi-site, randomized, double-blind, within-subject laboratory study was to assess the influence of CBD (0, 200, 400, 800 mg, p.o.) pretreatment on the reinforcing, subjective, cognitive, and physiological effects of smoked cannabis (0.01 (inactive), 5.30-5.80% THC). Non-treatment-seeking, healthy cannabis smokers (n=31; 17M, 14 F) completed eight outpatient sessions. CBD was administered 90 min prior to cannabis administration. The behavioral and cardiovascular effects of cannabis were measured at baseline and repeatedly throughout the session. A subset of participants (n=8) completed an additional session to measure plasma CBD concentrations after administration of the highest CBD dose (800 mg). Under placebo CBD conditions, active cannabis (1) was self-administered by significantly more participants than placebo cannabis and (2) produced significant, time-dependent increases in ratings of 'High', 'Good Effect', ratings of the cannabis cigarette (eg, strength, liking), and heart rate relative to inactive cannabis. CBD, which alone produced no significant psychoactive or cardiovascular effects, did not significantly alter any of these outcomes. Cannabis self-administration, subjective effects, and cannabis ratings did not vary as a function of CBD dose relative to placebo capsules. These findings suggest that oral CBD does not reduce the reinforcing, physiological, or positive subjective effects of smoked cannabis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect of inactive (0.01% THC) and active cannabis (5.30–5.80% THC) as a function of CBD dose and time, beginning at baseline (prior to capsule or cannabis administration) and ending 2 h after cannabis administration. ‘Cannabis' refers to the time in which cannabis (50% of a NIDA cigarette) was smoked. Error bars represent±SEM.
Figure 2
Figure 2
Effect of inactive (0.01% THC) and active cannabis (5.30–5.80% THC) as a function of CBD dose and time following cannabis administration. Data were collected for ‘Like' and ‘Strength' for 2 h after cannabis administration; street value ratings were collected for 1 h post cannabis administration.
Figure 3
Figure 3
Percentage of participants self-administering inactive (0.01% THC) or active (5.30–5.80% THC) cannabis, ie, purchasing at least one puff of cannabis available for self-administration (max=three puffs) as a function of CBD dose (left figure) and the number of cannabis puffs self-administered as a function of CBD dose. Error bars represent±SEM (right figure).
Figure 4
Figure 4
Effect of inactive (0.01% THC) and active cannabis (5.30–5.80% THC) as a function of CBD dose and time, beginning at baseline (prior to capsule or cannabis administration) and ending 2 h after cannabis administration. Bpm: beats per minute. See Figure 1 legend for details.
Figure 5
Figure 5
Individual and mean (filled circles, ±SEM) plasma CBD levels following administration (time=0 min) of 800 mg capsules through 6 h post dose.
See this image and copyright information in PMC

References

    1. Agurell S, Carlsson S, Lindgren J, Ohlsson A, Gillespie H, Hollister L (1981). Interactions of Δ11-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentographywith cannabinol and cannabidiol following oral administration in man. Assay of cannab. Experientia 37: 1090–1092. - PubMed
    1. Agurell S, Haldin M, Lindgren J, Ohlsson A, Widman M, Gillespie H et al (1986). Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 38: 21–43. - PubMed
    1. Benowitz NL, Nguyen T, Jones RT, Herning R, Bachman J (1980). Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction. Clin Pharmacol Ther 28: 115–120. - PubMed
    1. Bergamaschi M, Queiroz R, Chagas M, Oliveira D, Martinis B, Kapczinski F et al (2011. a). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 36: 1219–1226. - PMC - PubMed
    1. Bergamaschi M, Queiroz R, Zuardi A, Crippa J (2011. b). safety and side effects of cannabidiol, a cannabis sativa constituent. Curr Drug Safety 6: 237–249. - PubMed

Publication types